Haematopoietic stem cells, or HSCs, reside primarily in the bone marrow and continuously replenish the body’s blood and immune systems. Their ability to self-renew and produce multiple blood-cell lineages makes them attractive targets for treating inherited blood disorders, immune deficiencies and some cancers. Yet those same properties make them challenging to manipulate. Conventional gene-editing therapies often require stem cells to be removed from a patient, edited in a laboratory and then returned after conditioning treatment has cleared space in the bone marrow. An effective method for editing HSCs directly in vivo could simplify this process and potentially broaden access to cell and gene therapies.

The delivery system at the centre of the study is the lipid nanoparticle, a microscopic assembly of fats that can encapsulate and transport nucleic acids. Lipid nanoparticles became widely known through messenger RNA vaccines, but their potential extends far beyond vaccination. They can protect fragile genetic payloads from degradation, enter cells after administration and release their contents into the cytoplasm. For gene editing, such particles can be used to carry components that temporarily instruct a cell to cut, replace or regulate a selected DNA sequence. Unlike integrating viral vectors, many lipid-nanoparticle systems deliver their payload without permanently inserting a carrier genome into the recipient cell.

The major obstacle is specificity. When administered in the body, nanoparticles encounter proteins, membranes and immune cells throughout the circulation. Particles that accumulate in the liver, for example, may be highly effective for hepatic therapies but poorly suited to reaching bone-marrow stem cells. The researchers therefore developed targeted lipid nanoparticles intended to recognise and enter human HSCs more efficiently. Targeting can be achieved by displaying molecular ligands on the particle surface that bind receptors enriched on the desired cell type. Once attached, the particle may be internalised through receptor-mediated uptake, creating a route for the editing cargo to reach the cell’s interior.

This distinction between delivery and editing is crucial. A gene-editing system can be extraordinarily precise at the molecular level and still fail as a therapy if too little of it reaches the correct cells. HSCs represent only a small fraction of the cells in bone marrow, and they are surrounded by stromal cells, mature blood cells and other progenitors. A targeted particle must navigate this complex tissue, avoid premature clearance and release enough editing material inside the stem cell to generate a useful level of modification. At the same time, excessive exposure could damage cells or increase unintended editing, making the balance between potency and safety central to the design.

The study’s significance lies in its focus on human HSC biology rather than on delivery to a more accessible tissue. Editing these cells could have effects that persist for years because a successfully modified stem cell can divide and produce descendants across the blood system. That creates the possibility of correcting mutations at their source rather than repeatedly treating the symptoms produced by defective blood cells. It also raises the bar for safety: an alteration introduced into a long-lived stem-cell population could be inherited by many daughter cells, so researchers must evaluate both the intended genetic change and the possibility of unwanted genomic alterations.

Targeted lipid nanoparticles could offer several practical advantages over viral delivery platforms. Viruses have been engineered into powerful gene-transfer vehicles, but their manufacture, immune recognition, cargo limits and potential for persistent genetic activity can complicate treatment. Lipid nanoparticles are generally assembled from synthetic or semisynthetic components and can be designed to release transient editing instructions. Their chemistry can also be adjusted, allowing researchers to modify particle size, surface charge, stability and tissue distribution. These features make them a flexible platform, although they do not eliminate the challenges of immune responses, manufacturing consistency or delivery outside the liver.

The work also points toward a broader shift in gene therapy: from editing cells outside the body toward programming therapeutic changes in their native niches. In an ex vivo procedure, scientists can select cells, measure editing efficiency and remove poorly performing or damaged cells before infusion. In vivo treatment offers no such easy screening step. The nanoparticles must therefore perform their targeting, uptake and payload release within the patient, and the resulting cell population must be assessed through molecular and functional tests. Demonstrating meaningful editing in human HSCs is consequently an important milestone, but it is only one stage on the path toward clinical application.

Before such a method can be used routinely, researchers will need to establish how consistently the particles reach stem cells across individuals, how long the edited cells persist and whether blood production remains normal. Studies must also examine off-target editing, inflammatory reactions, dose limits and the behaviour of edited cells over extended periods. Questions about delivery to different bone-marrow compartments, the effects of preconditioning and the ability to adapt the system to different disease-associated mutations will be equally important. The therapeutic promise of the platform will ultimately depend not only on editing efficiency, but on whether it can deliver durable benefit with a risk profile acceptable for patients who may otherwise require lifelong treatment.

The report by Luo, Zhu and Mitchell marks a notable advance in the effort to make in vivo HSC gene editing technically achievable. By combining cell-selective targeting with the adaptable chemistry of lipid nanoparticles, the researchers address the delivery problem that has constrained many gene-editing concepts. The approach does not yet remove the biological and regulatory hurdles facing in vivo stem-cell therapy, but it provides a framework for pursuing treatments that act within the bone marrow rather than relying entirely on laboratory manipulation. If future studies confirm precise, durable and safe editing, targeted nanoparticles could help transform inherited blood disorders from conditions managed over a lifetime into diseases corrected at the level of the stem cells that sustain the blood system.

Subject of Research: Targeted lipid nanoparticle delivery for in vivo gene editing of human haematopoietic stem cells

Article Title: Targeted lipid nanoparticles unlock in vivo human haematopoietic stem cell gene editing

Article References: Luo, Z., Zhu, A.T. & Mitchell, M.J. Targeted lipid nanoparticles unlock in vivo human haematopoietic stem cell gene editing. Nature Biomedical Engineering (2026). https://doi.org/10.1038/s41551-026-01770-z

Image Credits: AI Generated

DOI: 10.1038/s41551-026-01770-z

Keywords: lipid nanoparticles, haematopoietic stem cells, in vivo gene editing, gene therapy, targeted delivery, bone marrow, regenerative medicine, nanomedicine

The review by Li, Zhu, Shen and colleagues examines two main routes for producing therapeutic immune cells. The first begins with peripheral blood mononuclear cells, a mixed population that includes lymphocytes and monocytes collected from a patient or donor. These cells can be isolated, activated and genetically modified before being returned to the recipient. The second route uses stem cells as a renewable starting material. Haematopoietic stem cells, which naturally generate blood and immune cells, can be expanded or redirected, while pluripotent stem cells can be differentiated into specialized immune populations under controlled laboratory conditions.

This distinction is important because conventional autologous cell therapies are laborious and variable. In an autologous process, a patient’s cells are collected, engineered and expanded before treatment. Disease, age, prior therapies and the condition of the patient’s immune system can all affect the quality and quantity of the starting material. Allogeneic manufacturing instead uses cells from a donor or a banked stem-cell line. A single engineered cell source may therefore be used to produce multiple treatment doses, allowing manufacturing to be performed in advance and under tightly controlled conditions.

Stem-cell engineering has expanded the range of immune cells that can be produced for therapy. T cells remain a central focus because they can identify abnormal cells through antigen-specific receptors and destroy them through cytotoxic mechanisms. Natural killer cells provide another route to immune-mediated killing and can recognize stressed or transformed cells without relying on the same antigen-recognition system as conventional T cells. Macrophages, which engulf material and influence inflammation, are also being developed as therapeutic agents. Each cell type offers distinct biological advantages, but each presents different challenges in generating a stable, potent and clinically useful product.

One of the most prominent technologies discussed in this field is the chimeric antigen receptor, or CAR. A CAR is a synthetic receptor introduced into an immune cell through genetic engineering. Its external binding region is designed to recognize a selected molecular marker, while internal signalling domains activate the cell after target engagement. CAR engineering has been particularly influential in T-cell therapy, but researchers are also adapting the technology for natural killer cells and macrophages. These CAR-equipped cells are intended to improve target recognition, strengthen activation and potentially overcome mechanisms that allow diseased cells to evade natural immunity.

Genetic modification can also be used to improve safety and immune compatibility. Researchers are investigating edits that reduce the ability of donor-derived cells to attack healthy recipient tissues, a complication associated with immune recognition across individuals. Other modifications may limit the capacity of therapeutic cells to trigger excessive inflammation, a process that can produce serious systemic effects. Gene engineering can additionally introduce “safety switches” or other control systems designed to eliminate or deactivate the cells if unwanted toxicity occurs. At the same time, reducing the expression of molecules recognized by the recipient’s immune system may help prolong the survival of transplanted cells.

The review also highlights the importance of differentiation platforms. Producing an immune cell from a stem cell is not simply a matter of adding one factor to a culture. Cells must receive carefully timed combinations of signalling molecules, growth factors and environmental cues that reproduce aspects of blood-cell development. Scientists are refining three-dimensional culture systems, feeder-free methods and scalable bioreactors to control this process. The objective is to generate large numbers of cells with a uniform identity, predictable function and minimal contamination by unwanted or incompletely differentiated cell types.

Manufacturing remains one of the field’s decisive tests. A clinically compatible process must preserve cell viability and activity while meeting strict standards for sterility, genetic stability and product consistency. Cells may need to be frozen, transported and stored without losing their therapeutic properties. Stem-cell-derived products also require extensive characterization to confirm that residual undifferentiated cells do not create safety risks. Advances in automation, closed-system processing and analytical technologies are helping researchers move from small laboratory batches toward reproducible production at a scale suitable for clinical use.

Early clinical evidence is beginning to shape expectations, but the review emphasizes that important questions remain. Researchers must determine how long engineered cells persist in the body, whether they continue functioning after repeated exposure to disease environments and how reliably they reach the tissues where they are needed. Tumours and chronic inflammatory conditions can suppress immune activity, while infectious diseases may impose rapidly changing biological pressures. Future studies will need to compare cell sources, genetic designs and manufacturing strategies directly, while also monitoring delayed toxicities and the long-term consequences of genome editing.

Together, these developments suggest that allogeneic immunotherapy could become a flexible platform rather than a single treatment type. Donor-derived and stem-cell-derived T cells, natural killer cells, macrophages and CAR-engineered variants may eventually be selected according to the disease, target and desired immune response. The review presents this convergence of gene engineering, stem-cell biology and bioprocessing as a foundation for more accessible cellular medicines. Its central message is that therapeutic success will depend not only on making immune cells powerful, but also on making them controllable, compatible, manufacturable and safe enough for broad clinical application.

Subject of Research: Allogeneic immunotherapy using genetically engineered and stem-cell-derived immune cells

Article Title: Allogeneic immunotherapy

Article References: Li, YR., Zhu, Y., Shen, X. et al. Allogeneic immunotherapy. Nat Rev Bioeng (2026). https://doi.org/10.1038/s44222-026-00468-w

Image Credits: AI Generated

DOI: 10.1038/s44222-026-00468-w

Keywords: Allogeneic immunotherapy, cell-based immunotherapy, stem cell engineering, T cells, natural killer cells, macrophages, CAR-engineered cells, gene editing, pluripotent stem cells, therapeutic cell manufacturing

Stem cell transplantation is a cornerstone therapy for various hematologic conditions such as leukemias and myelodysplastic syndromes. Traditionally, the efficacy of cord blood as a source for stem cell transplants has been curtailed by the relatively low number of hematopoietic stem cells available in a single cord blood unit. This cellular deficit often restricts effective engraftment and delays immune reconstitution. Addressing this challenge, the investigators explored a synergistic two-unit transplantation approach combining a single cord blood unit with a laboratory-expanded stem cell product derived from pooled cord blood donations. The phase 2 clinical trial results, recently published in the prestigious Journal of Clinical Oncology, highlight a remarkable one-year survival rate of 96% among 28 participants, with a notably low incidence of severe acute or chronic graft-versus-host disease (GVHD).

One of the study’s principal authors, Dr. Filippo Milano, articulated the unprecedented nature of this transplant modality, emphasizing that patients effectively received cells originating from nine distinct individuals. This intricate cellular mosaic underscores the complex interplay between donor graft components and host immune reconstitution dynamics. Importantly, the adjunctive stem cell product, dubbed dilanubicel and developed under the stewardship of senior author Dr. Colleen Delaney, is constituted from hematopoietic progenitors isolated from six to eight separate cord blood units. These progenitor cells undergo ex vivo expansion to achieve a therapeutically relevant cellular dose before infusion, a technique that marks a significant departure from conventional single-unit transplant paradigms.

The rationale behind utilizing a pooled, expanded progenitor cell product lies in its capacity to provide critical early immune support post-transplant. Although dilanubicel cells do not engraft permanently, their transient presence facilitates rapid hematopoietic recovery. Detailed analysis revealed that by one week post-transplant, patient peripheral blood was predominantly reconstituted by the infused pooled progenitor cells, effectively bridging the window until the long-term engraftment of the single cord blood unit occurs. This dual-phase engraftment profile mitigates the risks of prolonged cytopenias and infectious complications, which historically have hampered cord blood transplantation outcomes.

Beyond survival metrics, the trial data illuminate a substantial reduction in graft-versus-host disease manifestations. GVHD, a potentially fatal complication resulting from donor immune cells attacking recipient tissues, poses a critical barrier in stem cell transplantation. The absence of severe acute or chronic GVHD in this cohort attests to the immunological compatibility benefits intrinsic to cord blood grafts, enhanced by the strategic administration of the expanded progenitor product. This immunomodulatory effect may reflect nuanced interactions at the cellular and molecular levels, warranting further mechanistic investigations.

The patient cohort primarily comprised individuals diagnosed with various leukemias and myelodysplastic syndromes, representing a spectrum of hematologic malignancies with high unmet clinical needs. Most subjects have now reached nearly two years post-transplantation, maintaining robust remission status. One notable instance involved a patient who relapsed nearly a year post-transplant but subsequently achieved remission following additional treatment, underscoring both the potential and limitations inherent in current therapeutic strategies.

This study exemplifies translational research excellence, bridging basic stem cell biology with clinical innovation. The expansion methodology for dilanubicel utilized advanced culture conditions optimizing progenitor proliferation without inducing differentiation or loss of stemness. Such fine-tuned ex vivo manipulation is emblematic of cutting-edge regenerative medicine, harnessing the intrinsic plasticity of cord blood stem cells. Moreover, the collaborative fabric weaving together the Fred Hutch research community and commercial partner Deverra Therapeutics underscores the critical synergy between academia and industry in pioneering new therapeutics.

As with all early-phase clinical trials, cautious optimism is warranted. While these results are promising, larger-scale studies are necessary to validate efficacy, delineate long-term outcomes, and evaluate safety across broader patient populations. The therapy remains investigational, with regulatory approval yet to be secured. However, the implications of enabling more widespread use of cord blood transplants—particularly for patients from ethnically diverse backgrounds who often lack matched donors—are profound, with the potential to democratize access to curative stem cell therapies.

Dr. Milano’s vision includes expanding this therapeutic platform through additional funding avenues, intending to extend these benefits to a larger patient demographic. As the field moves forward, integrating advanced cellular therapies such as pooled, expanded progenitors could reshape the clinical standards for hematopoietic transplantation, balancing efficacy, safety, and accessibility.

This research also raises intriguing scientific questions regarding the mechanisms by which transient progenitor cells facilitate engraftment support and immune homeostasis. Future investigations exploring the molecular signaling pathways, cellular interactions, and niche occupancy may unlock further refinements to optimize transplant protocols.

Ultimately, this pioneering study reaffirms the critical importance of umbilical cord blood as a versatile and potent resource in regenerative medicine. By overcoming historic cellular quantity constraints through innovative cell expansion and pooling strategies, this approach holds promise to deliver enhanced therapeutic outcomes, offering new hope for patients confronting life-threatening blood diseases.

Subject of Research: People

Article Title: Safety and Clinical Outcomes of Pooled Donor, Non-Engrafting Expanded Progenitor Cells in Single-Unit Cord Blood Transplantation

News Publication Date: 27-Apr-2026

Keywords: Cord blood transplantation, hematopoietic stem cells, leukemias, myelodysplastic syndrome, stem cell expansion, graft-versus-host disease, dilanubicel, ex vivo stem cell culture, hematopoietic recovery, clinical trial, regenerative medicine, immunomodulation

ADA-SCID arises from mutations in the ADA gene, which encodes the enzyme adenosine deaminase—critical for the proper functioning of the immune system. The deficiency of this enzyme causes a profound impairment in immune defenses, rendering affected infants highly susceptible to severe infections from otherwise commonplace environmental exposure. Until now, treatment options have included bone marrow transplants from matched donors and lifelong enzyme replacement therapy. However, both methods carry significant risks, logistical challenges, and financial burdens, necessitating the development of safer, more sustainable alternatives.

The gene therapy in question employs a sophisticated technique that begins with harvesting hematopoietic stem cells from the patient’s own blood. These stem cells are pivotal as precursors to the entire spectrum of blood and immune cells responsible for pathogen defense. Using a genetically engineered lentiviral vector, researchers introduce a corrected, functional version of the ADA gene directly into these stem cells ex vivo. Upon re-infusion into the patient, the modified cells engraft and initiate the production of functional immune cells, thereby restoring the body’s ability to combat infections naturally and effectively.

Notably, the process of immune reconstitution following treatment is not instantaneous. It unfolds progressively over six to twelve months, as the transplanted stem cells proliferate and mature into diverse immune cell populations that re-establish robust immune competency. This prolonged timeline underscores both the complexity of hematopoietic cell biology and the careful clinical management required during recovery to mitigate risks.

In a recent publication in the New England Journal of Medicine, Dr. Donald Kohn of UCLA, a pioneering figure in gene therapy, along with colleagues including Dr. Katelyn Masiuk and Dr. Claire Booth, unveiled long-term follow-up data from a cohort of 62 children treated between 2012 and 2019. The results are compelling—59 of the 62 patients experienced successful restoration and maintenance of immune function, with no serious adverse events attributable to the gene therapy itself. The study includes an unprecedented 474 cumulative patient-years of observation, highlighting the sustained efficacy and safety of the approach over extended periods.

This dataset represents the most extensive and prolonged follow-up available for gene therapies targeting ADA-SCID, including five children living healthy lives more than a decade after their treatment. The stability of immune restoration beyond the initial recovery phase suggests that the gene-modified hematopoietic stem cells engraft effectively and persist, maintaining immune surveillance in the patients indefinitely. This durable response marks a significant milestone in the evolution of precision medicine for genetic immunodeficiencies.

Clinical observations reveal that all adverse effects recorded were either mild or moderate, frequently linked to preparatory procedures rather than the genetic intervention itself. Only three patients did not respond favorably to the gene therapy; these individuals subsequently resumed conventional treatment modalities such as bone marrow transplantation or enzyme replacement, demonstrating the continued viability of existing therapies as backup options.

Another crucial advancement of the study is the validation of cryopreservation techniques for the gene-corrected stem cells. More than half of the pediatric patients received frozen cells, which performed equivalently to those infused fresh. This cryopreservation breakthrough considerably expands access to treatment by allowing cellular products to be manufactured at centralized, specialized facilities and shipped globally, markedly reducing the need for patient travel to treatment centers.

The frozen stem cell protocol additionally facilitates rigorous quality control and precise dosing of conditioning chemotherapies, thereby optimizing patient safety and therapeutic consistency. These improvements in manufacturing and logistics herald a new era where gene therapies can be made broadly available to patients irrespective of geographic location or healthcare infrastructure disparities.

Looking forward, the research team at UCLA is actively engaged in preparing for regulatory approval, supported by funding from prominent institutions including the California Institute for Regenerative Medicine and various U.S. and U.K. health agencies. The therapy has been licensed to Rarity PBC, an organization dedicated to developing commercial-grade production pipelines in compliance with pharmaceutical standards, a critical step toward FDA market authorization anticipated within the next two to three years.

The transformative potential of this therapy is epitomized by the story of Eliana Nachem, a young patient who received the gene therapy at ten months old in 2014. Diagnosed as an infant, Eliana endured comprehensive isolation to avoid infections. A decade after treatment, she now leads an unrestricted, vibrant life, attending school and engaging in activities like sports—testament to the profound and lasting impact of this molecular medicine innovation.

Dr. Kohn and his colleagues emphasize that while the initial advent of gene therapy for ADA-SCID was groundbreaking, the current long-term data validate the treatment’s safety, durability, and feasibility, representing a paradigm shift in the management of inherited immune disorders. This success paves the way for broader applications of gene correction technologies in other hematologic and genetic diseases, ushering in a new generation of curative therapies built on the principles of genetic precision and cellular engineering.

As the community eagerly awaits FDA approval and subsequent clinical dissemination, this gene therapy stands as a beacon of hope and a model of interdisciplinary collaboration, combining virology, molecular genetics, immunology, and clinical medicine to conquer a once-fatal condition with the promise of normal, healthy lives for affected children worldwide.

Subject of Research: Adenosine deaminase severe combined immunodeficiency (ADA-SCID) and gene therapy interventions.

Article Title: Long-term Efficacy and Safety of Autologous Hematopoietic Stem Cell Gene Therapy for ADA-SCID.

News Publication Date: June 2024.

Web References:

• New England Journal of Medicine: https://www.nejm.org/media/doi/full/10.1056/NEJMoa2502754
• UCLA Dr. Donald Kohn profile: https://stemcell.ucla.edu/member-directory/donald-b-kohn-md
• Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA: https://stemcell.ucla.edu/
• UCLA Technology Development Group: https://tdg.ucla.edu/
• California Institute for Regenerative Medicine grant announcement: https://stemcell.ucla.edu/news/donald-kohn-awarded-147m-cirm-grant-advance-ada-scid-gene-therapy-toward-fda-approval

Keywords: Gene therapy, ADA-SCID, hematopoietic stem cells, immune reconstitution, lentiviral vector, cryopreservation, clinical outcomes, pediatric immunodeficiency, regenerative medicine, FDA approval, molecular genetics, viral vector therapy.